Polymorphic forms of the sodium salt of 4-tert- butyl -n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide

Abstract

Disclosed are novel polymorphic solvated and desolvated forms of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.

1 - 18 . (canceled) 
     
     
         19 . A crystalline form of a sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern containing diffraction angles, when measured using Cu K α  radiation, at about 6.5, 9.6, 10.6, 11.9, 14.4, 16.1, 17.7, 17.9, 19.3, 21.1, 22.0, 22.2, 23.4, 23.6, 24.4, 26.3, 27.7, 28.5, and 29.5°2θ. 
     
     
         20 . A crystalline form of a sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with  FIG. 4 . 
     
     
         21 . The crystalline form of  claim 20 , wherein the crystalline form provides a Raman spectrum containing peaks at about 654, 667, 737, 803, 855, 1077, 1122, 1160, 1311, 1461, 1536, 1592, 1609, and 1648 cm −1 . 
     
     
         22 . The crystalline form of  claim 20 , wherein the crystalline form provides a Raman spectrum substantially in accordance with  FIG. 9 . 
     
     
         23 . A pharmaceutical composition comprising the crystalline form according to  claim 20  and a pharmaceutically acceptable carrier. 
     
     
         24 . A method of preparing a pharmaceutical composition comprising admixing the crystalline form according to  claim 20  and a pharmaceutically acceptable carrier. 
     
     
         25 - 28 . (canceled) 
     
     
         29 . The crystalline form of  claim 20 , wherein the crystalline form differential scanning calorimetry thermogram profile is substantially in accordance with  FIG. 13 . 
     
     
         30 . The crystalline form of  claim 20 , wherein the crystalline form thermogravimetric analysis thermogram profile is substantially in accordance with  FIG. 17 . 
     
     
         31 . A method of treating a CCR9-mediated disorder, comprising administering an effective amount of the pharmaceutical composition of  claim 23  to a patient in need thereof. 
     
     
         32 . A method of treating a CCR9-mediated disorder in a subject in need thereof comprising administering to the subject an effective amount of the crystalline form of  claim 20 . 
     
     
         33 . The method of  claim 32  wherein the CCR9-mediated disorder is an inflammatory bowel disease. 
     
     
         34 . The method of  claim 33  wherein the inflammatory bowel disease is selected from Crohn's disease and ulcerative colitis. 
     
     
         35 . The method of  claim 32 , wherein the CCR9-mediated disorder is selected from allergic diseases, vaginitis, psoriasis, inflammatory dermatoses, vasculitis, spondyloarthropathies, scleroderma, asthma, respiratory allergic diseases, autoimmune diseases, graft rejection, graft-v-host disease, other diseases with inflammatory responses, fibrotic diseases, and irritable bowel syndrome. 
     
     
         36 . The method of  claim 35 , wherein the allergic disease is selected from systemic anaphylaxis or hypersensitivity responses, drug allergies, insect sting allergies, and food allergies. 
     
     
         37 . The method of  claim 35 , wherein the inflammatory dermatoses is selected from dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria and pruritus. 
     
     
         38 . The method of  claim 35 , wherein the respiratory allergic disease is selected from allergic asthma, allergic rhinitis, hypersensitivity lung disease. 
     
     
         39 . The method of  claim 35 , wherein the autoimmune disease is selected from fibromyalagia, scleroderma, ankylosing spondylitis, juvenile RA, Still's disease, polyarticular juvenile RA, pauciarticular juvenile RA, polymyalgia rheumatica, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, polyarticular arthritis, multiple sclerosis, systemic lupus erythematosus, type I diabetes, type II diabetes, and glomerulonephritis. 
     
     
         40 . The method of  claim 35 , wherein the other diseases with inflammatory responses are selected from atherosclerosis, myositis, neurodegenerative diseases, encephalitis, meningitis, hepatitis, nephritis, sepsis, sarcoidosis, allergic conjunctivitis, otitis, chronic obstructive pulmonary disease, sinusitis, Behcet's syndrome, and gout. 
     
     
         41 . The method of  claim 40 , wherein the neurodegenerative disease is Alzheimer's disease. 
     
     
         42 . The method of  claim 35 , wherein the fibrotic disease is pulmonary fibrosis.